Immunomedics wins $1.5 million award
Immunomedics of Morris Plains, NJ, was awarded $1.5 million by an arbitration panel last month in relation to its dispute with Pharmacia & Upjohn. Immunomedics had charged Pharmacia with breach of contract after it terminated a sales and licensing
Immunomedics of Morris Plains, NJ, was awarded $1.5 million by an arbitration panel last month in relation to its dispute with Pharmacia & Upjohn. Immunomedics had charged Pharmacia with breach of contract after it terminated a sales and licensing agreement for U.S. and Canadian sales of its CEA-Scan monoclonal-antibody-based imaging agent (SCAN 9/11/96).
Pharmacia had gained rights to CEA-Scan when it acquired the parent company of Adria Laboratories, the original licensee, in 1993. Pharmacia in 1995 canceled the agreement, saying it was scaling back its oncology sales force. Although the $1.5 million is a welcome addition to Immunomedics' balance sheet, it is much lower than the $60 million in damages that the company requested. Mallinckrodt now has U.S. and Canadian rights to CEA-Scan.
In other Immunomedics news, the company reported that its Dutch subsidiary, Immunomedics Europe, has entered into a packaging and distribution agreement with Eli Lilly for its LeukoScan infectious imaging agent and other potential products. Eli Lilly will have European rights to the agent, which the European Union in February 1997 approved for imaging bone infection.
What a New Mammography Study Reveals About BMI, Race, Ethnicity and Advanced Breast Cancer Risk
December 8th 2023In a new study examining population attributable risk proportions (PARPs) based on data from over three million screening mammography exams, researchers found that postmenopausal Black women had the highest BMI-related PARP and premenopausal Asian and Pacific Islander women had the highest breast density-related PARP for advanced breast cancer.
Study: Contrast-Enhanced Mammography Changes Surgical Plan in 22.5 Percent of Breast Cancer Cases
December 7th 2023Contrast-enhanced mammography detected additional lesions in 43 percent of patients and led to additional biopsies in 18.2 percent of patients, over half of whom had malignant lesions, according to a study of over 500 women presented at the recent Radiological Society of North America (RSNA) conference.
